• Cat-intel
  • MedIntelliX
  • Resources
  • About Us
  • Request Free Sample ×

    Kindly complete the form below to receive a free sample of this Report

    Leading companies partner with us for data-driven Insights

    clients tt-cursor

    HIV Drugs Market

    ID: MRFR/HC/6984-HCR
    110 Pages
    Kinjoll Dey
    September 2025

    HIV Drugs Market Research Report Information By Type (Nucleoside, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors, Fusion Inhibitors, CCR5 Antagonist), By End-User (Hospitals & Clinics, Specialty Centers) And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) –Market Forecast Till 2034

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    HIV Drugs Market Infographic
    Purchase Options
    $ 4,950.0
    $ 5,950.0
    $ 7,250.0

    HIV Drugs Market Summary

    The global HIV drugs market is projected to grow from 24.3 USD billion in 2024 to 37.0 USD billion by 2034.

    Key Market Trends & Highlights

    HIV Drugs Key Trends and Highlights

    • The market is expected to experience a compound annual growth rate of 3.9 percent from 2025 to 2034.
    • By 2035, the market valuation is anticipated to reach 37.0 USD billion, indicating robust growth potential.
    • In 2024, the market is valued at 24.3 USD billion, reflecting a strong foundation for future expansion.
    • Growing adoption of innovative treatment options due to increasing prevalence of HIV is a major market driver.

    Market Size & Forecast

    2024 Market Size 24.3 (USD Billion)
    2035 Market Size 37.0 (USD Billion)
    CAGR (2025-2035) 3.9%

    Major Players

    Boehringer Ingelheim International GmbH, Cipla Inc., Merck & Co., Inc., AbbVie Inc., Bristol-Myers Squibb Company, Teva Pharmaceutical Industries Ltd, Hoffmann-La Roche Ltd, Pfizer Inc., Aurobindo Pharma, Celltrion Healthcare Co., Ltd, ViiV Healthcare, Gilead Sciences, Inc.

    HIV Drugs Market Drivers

    Increasing Prevalence of HIV

    The rising prevalence of HIV globally serves as a primary driver for the Global HIV Drugs Market Industry. As of 2024, approximately 38 million people are living with HIV worldwide, with a notable concentration in sub-Saharan Africa. This demographic reality underscores the urgent need for effective antiretroviral therapies. The Global HIV Drugs Market Industry is projected to reach 24.3 USD Billion in 2024, reflecting the increasing demand for innovative treatment options. The persistent growth in HIV cases necessitates ongoing research and development, thereby propelling the market forward.

    Market Segment Insights

    HIV Drugs Type Insights

    The Human Immunodeficiency Virus Drugs Market segmentation, based on type, includes nucleoside, non-nucleoside reverse transcriptase inhibitors, protease inhibitors, integrase inhibitors, fusion inhibitors, and ccr5 antagonists. The nucleoside segment dominated the market, accounting for 45% of market revenue. This dominance is attributable to the rising demand for this medicine class due to improved outcomes in treating co-infections and HIV. This pharmacological class also includes the most progress. Due to improving outcomes in the pharmacological treatment of HIV and co-infections, this pharmaceutical class is increasingly in demand, which accounts for its dominance.

    HIV Drugs End User Insights

    The Human Immunodeficiency Virus Drugs market segmentation, based on End User, includes hospitals & clinics, and specialty centers. The hospitals & clinics category generated the most income (70.4%). Due to increased patients seeking HIV treatment in hospitals, the hospital pharmacies category is anticipated to have the biggest market share over the projection period. Furthermore, the segmental growth would be supported by hospital pharmacies' rising prescription antiretroviral drug sales for the treatment of HIV.

    Get more detailed insights about HIV Drugs Market Research Report - Forecast till 2034

    Regional Insights

    By region, the study provides market insights into North America, Europe, Asia-Pacific, and the Rest of the World. The North American Human Immunodeficiency Virus (HIV) Drugs market area will dominate this market; the rising incidence of HIV infection among Americans is to blame for this region's dominance. The Centres for Disease Control (CDC) estimated in 2021 that at the end of 2018, around 1.2 million people were living with HIV. Such a large patient group greatly increases the need for HIV medications. The population's awareness is another element influencing the progress of the region.

    Additionally, the existence of major players who provide cutting-edge HIV medications to treat HIV infection would further accelerate market growth.

    Further, the major countries studied in the market report are The U.S., Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

    Figure 2: Human Immunodeficiency Virus Drugs Market Share By Region 2022 (%)

    HUMAN IMMUNODEFICIENCY VIRUS (HIV) DRUGS MARKET SHARE BY REGION 2022

    Source: Secondary Research, Primary Research, Market Research Future Database and Analyst Review

    Europe's Human Immunodeficiency Virus Drugs market accounts for the second-largest market share due to the rise in HIV infection rates and the concentration of HIV medicine manufacturers in this area. Additionally, the growing strategic partnerships between European businesses will increase drug availability, supporting expanding the market in this area. Further, the German Human Immunodeficiency Virus (HIV) Drugs market held the largest market share. The UK Human Immunodeficiency Virus (HIV) Drugs market was the fastest-growing market in the European region.

    The Asia-Pacific Human Immunodeficiency Virus Drugs Market is expected to grow at the fastest CAGR from 2023 to 2034. This is due to the numerous HIV patients in highly populated nations like China and India. In addition, the market is projected to be driven by the rising number of treatment programs and the rising financing from the private sector and healthcare organizations. Moreover, China's Human Immunodeficiency Virus (HIV) Drugs market held the largest market share. The Indian Human Immunodeficiency Virus Drugs market was the fastest-growing market in the Asia-Pacific region.

    Key Players and Competitive Insights

    Leading market players are making significant R&D investments to diversify their product offerings, which would drive the market for Human Immunodeficiency Virus (HIV) Drugs to increase in size. Important market developments include new product releases, contractual agreements, mergers and acquisitions, greater investments, and collaboration with other organizations. Market participants also engage in several strategic actions to increase their worldwide presence. The Human Immunodeficiency Virus (HIV) Drugs industry must provide affordable products to grow and thrive in an increasingly competitive and challenging market environment.

    One of the primary business strategies manufacturers employ in the worldwide Human Immunodeficiency Virus (HIV) Drugs industry to assist customers and expand the market sector is manufacturing locally to reduce operating costs. In recent years, the Human Immunodeficiency Virus (HIV) Drugs industry has offered some of the most significant advantages to medicine. Major players in the Human Immunodeficiency Virus (HIV) Drugs market, including Bristol-Myers Squibb Company, Theratechnologies Inc. and others, are attempting to increase market demand by investing in research and development operations.

    Located in Foster City, California, Gilead Sciences, Inc. (/lid/) is an American biopharmaceutical company that specializes in researching and creating antiviral medications used to treat COVID-19, hepatitis B, hepatitis C, influenza, and HIV/AIDS. These medications include ledipasvir/sofosbuvir and sofosbuvir. Gilead is a component of the S&P 500 and the NASDAQ Biotechnology Index. In December 2020, gilead sciences, inc., announced a grant of USD 1.4 million for its 'Gilead Asia pacific rainbow award program' in the region.

    The program is a component of Gilead's effort to strengthen public-private partnerships in the Asia Pacific region to address issues encountered by patients who are infected with HIV.

    More than 150 individuals are employed by Theratechnologies, created in 1993 and operated in Canada, the US, and Europe. Theratechnologies, headquartered in Montreal, Quebec (Canada), commercializes two HIV medications and researches HIV, NASH, and oncology. In July 2020, Theratechnologies Europe Limited, a branch of Theratechnologies Inc. in Europe, worked with Loxxess to distribute the antiviral medication Trogarzo throughout the continent.

    Key Companies in the HIV Drugs Market market include

    Industry Developments

    • Q2 2025: Yeztugo Lenacapavir Is Now the First and Only FDA Approved HIV Prevention Option Offering 6 Months of Protection Gilead Sciences announced FDA approval of Yeztugo (lenacapavir), the first and only twice-yearly injectable HIV-1 capsid inhibitor for pre-exposure prophylaxis (PrEP), based on Phase 3 data showing ≥99.9% efficacy in preventing HIV infection.
    • Q3 2025: Merck to Present New Data Highlighting Research Advancements Across its HIV Prevention and Treatment Pipeline at IAS 2025 Merck announced it will present new Phase 2 and Phase 3 clinical data on its HIV pipeline, including the investigational oral NRTTI MK-8527 for monthly PrEP, at the International AIDS Society Conference in July 2025.
    • Q3 2025: CHAI publishes second edition of the HIV Market Impact Memo: Up to 68% reductions in oral PrEP initiations, HIV testing and monitoring, and treatment initiations (Q4 2024 – Q1 2025) CHAI reported significant reductions in HIV service delivery—including PrEP initiations and treatment starts—across 13 low- and middle-income countries due to funding cuts, warning of increased infections and deaths if trends continue.

    HIV Drugs

    Future Outlook

    HIV Drugs Market Future Outlook

    The Global HIV Drugs Market is projected to grow at a 3.9% CAGR from 2024 to 2034, driven by advancements in treatment options, increasing awareness, and supportive government policies.

    New opportunities lie in:

    • Invest in personalized medicine approaches to enhance treatment efficacy and patient adherence.
    • Expand access to generics in emerging markets to capture price-sensitive segments.
    • Leverage digital health technologies for remote patient monitoring and adherence support.

    By 2035, the market is expected to demonstrate robust growth, reflecting advancements in treatment and increased global access.

    Market Segmentation

    HIV Drugs Type Outlook

    •  Nucleoside
    • Non-Nucleoside Reverse Transcriptase Inhibitors
    • Protease Inhibitors
    • Integrase Inhibitors
    • Fusion Inhibitors
    • CCR5 Antagonist

    HIV Drugs End User Outlook

    • Hospitals & Clinics
    • Specialty Centers

    HIV Drugs Regional Outlook

    • US
    • Canada

    Report Scope

    Report Attribute/Metric Details
    Market Size 2024   24.28 (USD Billion)
    Market Size 2025   25.23 (USD Billion)
    Market Size 2034   35.61 (USD Billion)
    Compound Annual Growth Rate (CAGR)    3.90 % (2025 - 2034)
    Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
    Base Year 2024
    Market Forecast Period 2025 - 2034
    Historical Data 2020 - 2024
    Report Coverage Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends
    Segments Covered Type, End User, and Region
    Geographies Covered North America, Europe, Asia Pacific, and the Rest of the World
    Countries Covered The U.S., Canada, German, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil
    Key Companies Profiled  Boehringer Ingelheim International GmbH (Germany)Cipla Inc. (India)Merck & Co., Inc. (US)AbbVie Inc. (US)Bristol-Myers Squibb Company (US)Teva Pharmaceutical Industries Ltd (Israel)Gilead Sciences, Inc. (US)Hoffmann-La Roche Ltd (Switzerland)Pfizer Inc. (US)Aurobindo Pharma (India)Celltrion Healthcare Co., Ltd (South Korea)ViiV Healthcare (UK)
    Key Market Opportunities Growing funding for the treatment drug of HIV
    Key Market Dynamics Increase in patient of HIV

    Market Highlights

    Author
    Kinjoll Dey
    Research Analyst Level I

    He is an extremely curious individual currently working in Healthcare and Medical Devices Domain. Kinjoll is comfortably versed in data centric research backed by healthcare educational background. He leverages extensive data mining and analytics tools such as Primary and Secondary Research, Statistical Analysis, Machine Learning, Data Modelling. His key role also involves Technical Sales Support, Client Interaction and Project management within the Healthcare team. Lastly, he showcases extensive affinity towards learning new skills and remain fascinated in implementing them.

    Leave a Comment

    FAQs

    How much is the Human Immunodeficiency Virus (HIV) Drugs market?

    The Human Immunodeficiency Virus (HIV) Drugs market size was valued at USD 22.5 Billion in 2022.

    What is the growth rate of the Human Immunodeficiency Virus (HIV) Drugs market?

    The market is projected to grow at a CAGR of 3.90% during the forecast period, 2023-2034.

    Which region held the largest market share in the Human Immunodeficiency Virus (HIV) Drugs market?

    North America had the largest share in the market

    Who are the key players in the Human Immunodeficiency Virus (HIV) Drugs market?

    The key players in the market are Boehringer Ingelheim International GmbH (Germany,)Cipla Inc. (India),Merck & Co., Inc. (US),AbbVie Inc. (US),Bristol-Myers Squibb Company (US).

    Which type led the Human Immunodeficiency Virus (HIV) Drugs market?

    The Nucleoside category dominated the market in 2022.

    Which End User had the largest market share in the Human Immunodeficiency Virus (HIV) Drugs market?

    The hospital and clinic had the largest share in the market.

    HIV Drugs Market Research Report - Forecast till 2034 Infographic
    Free Sample Request

    Kindly complete the form below to receive a free sample of this Report

    Customer Stories

    “I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

    Victoria Milne Founder
    Case Study
    Chemicals and Materials